Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteopathic Medicine | 5 | 2020 | 16 | 1.670 |
Why?
|
| Drugs, Generic | 2 | 2022 | 6 | 1.470 |
Why?
|
| Education, Medical | 3 | 2020 | 68 | 1.300 |
Why?
|
| Training Support | 5 | 2020 | 10 | 1.080 |
Why?
|
| Career Choice | 4 | 2020 | 53 | 1.020 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2023 | 4 | 0.910 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2022 | 8 | 0.730 |
Why?
|
| Students, Medical | 2 | 2020 | 102 | 0.730 |
Why?
|
| Anemia, Hemolytic | 1 | 2022 | 22 | 0.720 |
Why?
|
| Drug Industry | 1 | 2021 | 15 | 0.690 |
Why?
|
| Primary Health Care | 2 | 2020 | 169 | 0.660 |
Why?
|
| Pica | 1 | 2020 | 1 | 0.640 |
Why?
|
| Medicine | 1 | 2020 | 22 | 0.640 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 27 | 0.620 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 44 | 0.600 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 16 | 0.590 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 16 | 0.590 |
Why?
|
| Drug Costs | 4 | 2023 | 17 | 0.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 433 | 0.580 |
Why?
|
| Sarcoma | 1 | 2019 | 29 | 0.580 |
Why?
|
| United States | 9 | 2023 | 2252 | 0.560 |
Why?
|
| Publication Bias | 4 | 2017 | 11 | 0.520 |
Why?
|
| Humans | 26 | 2023 | 29078 | 0.520 |
Why?
|
| Internship and Residency | 1 | 2020 | 263 | 0.510 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 301 | 0.480 |
Why?
|
| Cell Differentiation | 1 | 2019 | 428 | 0.480 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1015 | 0.380 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2021 | 5 | 0.340 |
Why?
|
| Commerce | 2 | 2022 | 61 | 0.340 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 33 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 171 | 0.270 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 686 | 0.260 |
Why?
|
| Adult | 6 | 2021 | 8080 | 0.240 |
Why?
|
| Retrospective Studies | 4 | 2021 | 2651 | 0.240 |
Why?
|
| Young Adult | 4 | 2021 | 2855 | 0.220 |
Why?
|
| Medicare Part B | 1 | 2023 | 3 | 0.210 |
Why?
|
| Neoplasms | 2 | 2023 | 882 | 0.200 |
Why?
|
| Male | 6 | 2022 | 14049 | 0.200 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 1 | 2022 | 1 | 0.190 |
Why?
|
| Encephalitis, Tick-Borne | 1 | 2022 | 1 | 0.190 |
Why?
|
| Encephalitis | 1 | 2022 | 18 | 0.190 |
Why?
|
| Coombs Test | 1 | 2022 | 2 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 44 | 0.180 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 101 | 0.180 |
Why?
|
| Patents as Topic | 1 | 2021 | 5 | 0.180 |
Why?
|
| Prescription Drugs | 1 | 2022 | 15 | 0.180 |
Why?
|
| Adolescent | 2 | 2020 | 3233 | 0.180 |
Why?
|
| Female | 5 | 2021 | 15740 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 379 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 413 | 0.160 |
Why?
|
| Erdheim-Chester Disease | 1 | 2020 | 1 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 105 | 0.160 |
Why?
|
| Mitoxantrone | 1 | 2020 | 2 | 0.160 |
Why?
|
| Retreatment | 1 | 2020 | 13 | 0.160 |
Why?
|
| Craving | 1 | 2020 | 18 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2020 | 37 | 0.160 |
Why?
|
| Middle Aged | 3 | 2021 | 7458 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 194 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2019 | 12 | 0.150 |
Why?
|
| Financing, Government | 1 | 2019 | 7 | 0.150 |
Why?
|
| Aged | 4 | 2023 | 5627 | 0.150 |
Why?
|
| Recurrence | 1 | 2020 | 328 | 0.150 |
Why?
|
| Testis | 1 | 2019 | 40 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2022 | 486 | 0.140 |
Why?
|
| Lung | 1 | 2021 | 385 | 0.140 |
Why?
|
| Medically Underserved Area | 1 | 2018 | 19 | 0.140 |
Why?
|
| Cisplatin | 1 | 2019 | 186 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 360 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 480 | 0.130 |
Why?
|
| Intention | 1 | 2018 | 79 | 0.130 |
Why?
|
| Neurology | 1 | 2017 | 11 | 0.130 |
Why?
|
| Hematology | 1 | 2017 | 25 | 0.130 |
Why?
|
| Publications | 1 | 2017 | 24 | 0.130 |
Why?
|
| Publishing | 1 | 2017 | 34 | 0.130 |
Why?
|
| Arthroplasty | 1 | 2016 | 3 | 0.130 |
Why?
|
| Shoulder | 1 | 2016 | 8 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2016 | 14 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2020 | 1286 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 221 | 0.120 |
Why?
|
| Registries | 1 | 2016 | 398 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2020 | 2430 | 0.100 |
Why?
|
| Obesity | 1 | 2017 | 705 | 0.090 |
Why?
|
| Mutation | 2 | 2020 | 873 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1009 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2023 | 30 | 0.050 |
Why?
|
| Filgrastim | 1 | 2023 | 7 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2023 | 99 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 20 | 0.050 |
Why?
|
| Economic Competition | 1 | 2022 | 7 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 40 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 126 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 82 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 288 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2020 | 24 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 31 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2020 | 73 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 137 | 0.040 |
Why?
|
| Indoles | 1 | 2020 | 111 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 815 | 0.040 |
Why?
|
| Professional Practice Location | 1 | 2018 | 4 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2017 | 8 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2017 | 38 | 0.030 |
Why?
|
| Research | 1 | 2017 | 93 | 0.030 |
Why?
|